| Entry |
|
|---|
| Name |
Plerixafor (JAN/USAN/INN);
Mozobil (TN)
|
|---|
| Product |
|
|---|
| Formula |
C28H54N8
|
|---|
| Exact mass |
502.4471
|
|---|
| Mol weight |
502.782
|
|---|
| Structure |
   |
|---|
| Remark |
| Therapeutic category: | 3399 |
|
|---|
| Efficacy |
Antineoplastic, Chemokine receptor type 4 (CXCR4) antagonist |
|---|
| Disease |
|
|---|
| Comment |
Hematopoietic stem cell mobilizer
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AX Other immunostimulants
L03AX16 Plerixafor
D08971 Plerixafor (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Products/Modifiers/Volume Expanders
Blood Formation Modifiers
Plerixafor
D08971 Plerixafor (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D08971 Plerixafor (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Chemokine receptors
CXCR4 (CD184)
D08971 Plerixafor (JAN/USAN/INN) <JP/US>
Antineoplastics [br08340.html]
D08971
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08971
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08971
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08971
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08971
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 36
1 C1x C 18.4800 -9.4500
2 C1x C 18.4800 -10.8500
3 C1x C 20.9049 -10.8500
4 C1x C 20.9049 -9.4500
5 N1x N 19.6924 -8.7500
6 N1x N 17.2676 -11.5500
7 C1x C 17.2676 -12.9500
8 C1x C 18.4800 -13.6500
9 C1x C 20.9049 -13.6500
10 N1y N 22.1173 -12.9500
11 C1x C 22.1173 -11.5500
12 C1x C 18.4800 -15.0500
13 N1x N 19.6924 -15.7500
14 C1x C 20.9049 -15.0500
15 C1b C 23.3318 -13.6512
16 C8y C 24.5283 -12.9602
17 C8x C 25.7151 -13.6454
18 C8x C 26.9275 -12.9454
19 C8y C 26.9275 -11.5454
20 C8x C 25.7407 -10.8602
21 C8x C 24.5283 -11.5602
22 C1b C 28.1546 -10.8366
23 N1y N 29.3618 -11.5334
24 C1x C 29.3624 -12.9496
25 C1x C 30.5751 -13.6492
26 C1x C 30.5740 -10.8330
27 C1x C 32.9989 -10.8321
28 C1x C 32.9984 -9.4321
29 N1x N 31.7857 -8.7326
30 C1x C 30.5735 -9.4330
31 C1x C 32.9999 -13.6321
32 N1x N 34.2121 -12.9317
33 C1x C 34.2116 -11.5317
34 C1x C 30.5757 -15.0492
35 N1x N 31.7884 -15.7487
36 C1x C 33.0005 -15.0482
BOND 38
1 1 2 1
2 3 4 1
3 4 5 1
4 1 5 1
5 2 6 1
6 6 7 1
7 7 8 1
8 9 10 1
9 10 11 1
10 3 11 1
11 8 12 1
12 12 13 1
13 13 14 1
14 14 9 1
15 10 15 1
16 15 16 1
17 16 17 2
18 17 18 1
19 18 19 2
20 19 20 1
21 20 21 2
22 16 21 1
23 19 22 1
24 22 23 1
25 23 24 1
26 24 25 1
27 23 26 1
28 27 28 1
29 28 29 1
30 29 30 1
31 26 30 1
32 31 32 1
33 32 33 1
34 27 33 1
35 25 34 1
36 34 35 1
37 35 36 1
38 36 31 1
|
|---|
